Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapiesIncludes two late-stage, potential best-in-class ROS1 (zidesamtinib) and
  • Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies
  • Includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for non-small cell lung cancer (NSCLC), currently under US FDA review for 2026 approvals
  • Accelerates entry into lung cancer, providing a platform for expansion with Ris-Rez, GSK's B7-H3 antibody-drug conjugate (ADC)
  • Acquisition expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation